Human ES-derived cardiomyocytes regenerate non-human primate hearts

ceazon

0 ^3 _. Y" H/ I; H2 J, h/ N& r& ?6 C* E4 B4 Z

& f- x8 y% C( h8 [% ?3 }1 }5 g6 Y7 X: d" ^- H2 O$ w, f  i
Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts
5 H* Y3 {4 l% g. `! m5 Y5 l$ |( t0 V6 w' |+ L6 f2 a' g

4 _- B( q! }4 Z8 d/ C6 n: ?: R& G# b: d4 L! n0 b5 \5 h- `+ R
Pluripotent stem cells provide a potential solution to current epidemic rates of heart failure1 by providing human cardiomyocytes to support heart regeneration2. Studies of human embryonic-stem-cell-derived cardiomyocytes (hESC-CMs) in small-animal models have shown favourable effects of this treatment. However, it remains unknown whether clinical-scale hESC-CM transplantation is feasible, safe or can provide sufficient myocardial regeneration. Here we show that hESC-CMs can be produced at a clinical scale (more than one billion cells per batch) and cryopreserved with good viability. Using a non-human primate model of myocardial ischaemia followed by reperfusion, we show that that cryopreservation and intra-myocardial delivery of one billion hESC-CMs generates extensive remuscularization of the infarcted heart. The hESC-CMs showed progressive but incomplete maturation over a 3-month period. Grafts were perfused by host vasculature, and electromechanical junctions between graft and host myocytes were present within 2 weeks of engraftment. Importantly, grafts showed regular calcium transients that were synchronized to the host electrocardiogram, indicating electromechanical coupling. In contrast to small-animal models7, non-fatal ventricular arrhythmias were observed in hESC-CM-engrafted primates. Thus, hESC-CMs can remuscularize substantial amounts of the infarcted monkey heart. Comparable remuscularization of a human heart should be possible, but potential arrhythmic complications need to be overcome.

bubble_w

求原文

cortex

原文